Short answer · Medically reviewed summary · Last updated: 2026-05-08
Acute myelogenous leukemia (AML) was first described in the mid-19th century as a "blood suppuration," evolving from a mysterious, fatal condition into a complex malignancy defined by specific genetic mutations. Today, our understanding of Acute myelogenous leukemia (AML) has shifted from broad clinical classification to precision molecular medicine, significantly improving diagnostic accuracy and therapeutic targeting. When was Acute myelogenous leukemia (AML) first identified? The clinical recognition of Acute myelogenous leukemia (AML) dates back to 1845, when physicians Rudolf Virchow and John Hughes Bennett independently described patients with an unusual "white blood" condition.
What is the history of Acute myelogenous leukemia (AML)?
History of Acute myelogenous leukemia (AML): when and how it was discovered, and the milestones in research since, medically reviewed.
Acute myelogenous leukemia (AML) was first described in the mid-19th century as a "blood suppuration," evolving from a mysterious, fatal condition into a complex malignancy defined by specific genetic mutations. Today, our understanding of Acute myelogenous leukemia (AML) has shifted from broad clinical classification to precision molecular medicine, significantly improving diagnostic accuracy and therapeutic targeting.
When was Acute myelogenous leukemia (AML) first identified?
The clinical recognition of Acute myelogenous leukemia (AML) dates back to 1845, when physicians Rudolf Virchow and John Hughes Bennett independently described patients with an unusual "white blood" condition. Virchow coined the term "leukemia" (Greek for "white blood"), though it took several decades for researchers to distinguish the myeloid lineage from other forms of leukemia. By the early 20th century, the development of specialized staining techniques allowed pathologists to finally characterize the distinct morphology of Acute myelogenous leukemia (AML) cells.
How has the treatment of Acute myelogenous leukemia (AML) evolved?
For most of history, an Acute myelogenous leukemia (AML) diagnosis was considered universally fatal. The treatment landscape transformed dramatically during the 20th century:
- 1940s-1960s: The birth of chemotherapy; the introduction of drugs like cytarabine and daunorubicin established the "7+3" regimen, which remains a backbone of therapy today.
- 1970s-1980s: The refinement of hematopoietic stem cell transplantation offered the first potential for long-term remission in high-risk patients.
- 2000s-Present: The era of targeted therapy, utilizing small molecule inhibitors and monoclonal antibodies to attack specific genetic drivers of the disease.
How have genetics changed our understanding of the disease?
Modern genomic sequencing has revolutionized the management of Acute myelogenous leukemia (AML). We now understand that it is not one single disease, but a collection of distinct biological entities driven by specific mutations (such as FLT3, NPM1, or IDH1/2). This shift away from purely microscopic observation toward molecular profiling allows clinicians to predict prognosis and select personalized therapies for the 62 members of our DiseaseMaps.org community and patients worldwide.
Next steps
- Consult with a hematologist-oncologist to discuss molecular testing and your specific genetic profile.
- Connect with the 62 community members on DiseaseMaps.org to share experiences and coping strategies.
- Explore clinical trial opportunities through the NIH or specialized cancer centers for the latest experimental therapies.
Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment.
References
- NIH National Cancer Institute: Adult Acute Myeloid Leukemia Treatment (PDQ®)
- Orphanet: Acute Myeloid Leukemia
- OMIM (Online Mendelian Inheritance in Man): Leukemia, Acute Myeloid
- Leukemia & Lymphoma Society (LLS): Understanding AML
